Flunixin Meglumine equivalent to 50 mg/mL Flunixin
 
A non-steroidal, anti-inflammatory agent with analgesic and anti-pyretic activity.

Indication: 
Horses: For the alleviation of inflammation and pain associated with musculoskeletal disorders and for the alleviation of visceral pain and inflammation associated with colic.
Cattle: As an aid in the management of musculoskeletal disorders.
Pigs: As an aid in the treatment of mastitis, metritis, agalactia syndrome (MMA or lactational failure) in sows.
Dogs: As a supportive therapy for arthritis and traumatic injuries

Contraindication: 
This product is contraindicated for use in cats. In the absence of any specific studies in pregnant target animals such use is contraindicated.
 
Dosage and Administration
Horses:
Musculoskeletal disorders: 1.1 mg per kg (1 mL/45 kg bodyweight) once daily by IV (intravenous) or IM (intramuscular) injection for up to 5 days.
Alleviation of pain associated with colic: 1.1 mg per kg bodyweight. Given IV or IM once daily for up to 5 days. Cause of colic should be determined and treated with concomitant therapy.
 
Cattle:
Musculoskeletal indications, visceral pain: 2.2 mg/kg IV once daily for 3 – 5 days.
 
Pigs:
MMA syndrome: 2.2 mg/kg (2 mL/45 kg) by deep IM injection (5 cm). One or two injections 12 hours apart.
 
Dogs: 
Arthritis and traumatic injuries: 1.0 mg per kg bodyweight IV (0.2 mL/9 kg bodyweight). Once daily for 2-3 days. Dose rate should not be exceeded.
 
Precautions:
Flunixin should be used with caution in conjunction with ulcerogenic or nephrotoxic agents, in cases of pre-existing gastrointestinal ulceration or renal disease, and in hypovolaemic patients. Care should be exercised in the use of flunixin in patients with hepatic disease, haematological disorders or severe cardiac failure. As with other NSAIDs, flunixin should be used cautiously in conjunction with highly proteinbound drugs such as phenytoin, valproic acid, oral anticoagulants, other anti-inflammatory agents, and sulfonamides.
 
Flunixin, when used in the therapy of equine colic, may mask the behavioural and cardiopulmonary signs associated with endotoxaemia or intestinal devitalisation. Care should be taken to avoid intra-arterial injection of flunixin as it may cause transient CNS stimulation, ataxia, hyperventilation, and muscle weakness.
 
Flunixin may be slightly irritant when administered by intramuscular injection to young animals or if injected too superficially into older animals
 
Adverse Effects: 
Occasional cases of localised swelling, induration, muscle stiffness, and sweating have been reported following intramuscular injection of flunixin in horses.

Withholding Times: 
MILK: Nil
MEAT:
Cattle producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 1 day of the last treatment.
Pigs producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 3 days of the last treatment.
Horses producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 63 days of the last treatment.

Other Information: 
Store below 25°C (room temperature). Do not freeze. Store upright. Use the contents of the vial within 28 days of initial broaching and discard any unused portion.
 
Read full product label and leaflet before use